Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

103 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Correction to: The 68Ga/177Lu-theragnostic concept in PSMA-targeting of metastatic castration-resistant prostate cancer: impact of post-therapeutic whole-body scintigraphy in the follow-up.
Maffey-Steffan J, Scarpa L, Svirydenka A, Nilica B, Mair C, Buxbaum S, Bektic J, von Guggenberg E, Uprimny C, Horninger W, Virgolini I. Maffey-Steffan J, et al. Among authors: buxbaum s. Eur J Nucl Med Mol Imaging. 2020 Mar;47(3):740. doi: 10.1007/s00259-019-04660-6. Eur J Nucl Med Mol Imaging. 2020. PMID: 31863137 Free PMC article.
The 68Ga/177Lu theragnostic concept in PSMA targeting of castration-resistant prostate cancer: correlation of SUVmax values and absorbed dose estimates.
Scarpa L, Buxbaum S, Kendler D, Fink K, Bektic J, Gruber L, Decristoforo C, Uprimny C, Lukas P, Horninger W, Virgolini I. Scarpa L, et al. Among authors: buxbaum s. Eur J Nucl Med Mol Imaging. 2017 May;44(5):788-800. doi: 10.1007/s00259-016-3609-9. Epub 2017 Jan 12. Eur J Nucl Med Mol Imaging. 2017. PMID: 28083690 Clinical Trial.
Comparison of [68Ga]Ga-PSMA-11 PET/CT with [18F]NaF PET/CT in the evaluation of bone metastases in metastatic prostate cancer patients prior to radionuclide therapy.
Uprimny C, Svirydenka A, Fritz J, Kroiss AS, Nilica B, Decristoforo C, Haubner R, von Guggenberg E, Buxbaum S, Horninger W, Virgolini IJ. Uprimny C, et al. Among authors: buxbaum s. Eur J Nucl Med Mol Imaging. 2018 Oct;45(11):1873-1883. doi: 10.1007/s00259-018-4048-6. Epub 2018 May 16. Eur J Nucl Med Mol Imaging. 2018. PMID: 29766246
Radiation exposure after 177Lu-DOTATATE and 177Lu-PSMA-617 therapy.
Mair C, Warwitz B, Fink K, Scarpa L, Nilica B, Maffey-Steffan J, Buxbaum S, Virgolini IJ. Mair C, et al. Among authors: buxbaum s. Ann Nucl Med. 2018 Aug;32(7):499-502. doi: 10.1007/s12149-018-1264-x. Epub 2018 May 23. Ann Nucl Med. 2018. PMID: 29797003
The 68Ga/177Lu-theragnostic concept in PSMA-targeting of metastatic castration-resistant prostate cancer: impact of post-therapeutic whole-body scintigraphy in the follow-up.
Maffey-Steffan J, Scarpa L, Svirydenka A, Nilica B, Mair C, Buxbaum S, Bektic J, von Guggenberg E, Uprimny C, Horninger W, Virgolini I. Maffey-Steffan J, et al. Among authors: buxbaum s. Eur J Nucl Med Mol Imaging. 2020 Mar;47(3):695-712. doi: 10.1007/s00259-019-04583-2. Epub 2019 Nov 27. Eur J Nucl Med Mol Imaging. 2020. PMID: 31776632 Free PMC article.
Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle.
Nilica B, Waitz D, Stevanovic V, Uprimny C, Kendler D, Buxbaum S, Warwitz B, Gerardo L, Henninger B, Virgolini I, Rodrigues M. Nilica B, et al. Among authors: buxbaum s. Eur J Nucl Med Mol Imaging. 2016 Aug;43(9):1585-92. doi: 10.1007/s00259-016-3328-2. Epub 2016 Feb 27. Eur J Nucl Med Mol Imaging. 2016. PMID: 26922350 Free PMC article.
Quality of Life in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors Receiving Peptide Receptor Radionuclide Therapy: Information from a Monitoring Program in Clinical Routine.
Martini C, Buxbaum S, Rodrigues M, Nilica B, Scarpa L, Holzner B, Virgolini I, Gamper EM. Martini C, et al. Among authors: buxbaum s. J Nucl Med. 2018 Oct;59(10):1566-1573. doi: 10.2967/jnumed.117.204834. Epub 2018 Jul 24. J Nucl Med. 2018. PMID: 30042164 Free article.
Repeated treatment with low dose of [131I]MIBG with good response and without toxicity.
Rossetti LM, Kroiss AS, Uprimny C, Buxbaum S, Virgolini IJ. Rossetti LM, et al. Among authors: buxbaum s. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2021 Apr 23:S2253-654X(20)30140-2. doi: 10.1016/j.remn.2020.08.003. Online ahead of print. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2021. PMID: 33903086 English, Spanish. No abstract available.
103 results